Vildagliptin
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Diabetes & Endocrine treatment.
🧴 Clinical Application
Take orally with water, with or without food. Standard dose is 50 mg twice daily (morning and evening) or 100 mg SR once daily. When added to a sulfonylurea, a 50 mg once-daily morning dose is used to prevent hypoglycemia.
⚠️ Side Effects
Common: Headache, tremor, dizziness, nausea, nasopharyngitis, mild peripheral edema. Rare/Severe: Hepatic dysfunction (transaminitis, rare acute hepatitis), acute pancreatitis, and bullous pemphigoid.
🛡️ Safety Warnings
Liver function tests (ALT/AST) must be conducted prior to initiation, at 3-month intervals during the first year, and periodically thereafter; do not initiate if ALT/AST > 3x ULN. Reduce dose to 50 mg once daily in moderate-to-severe renal impairment. Discontinue if persistent abdominal pain develops.
Jan Aushadhi Products containing Vildagliptin
Found 16 generic formulation(s) containing this active ingredient.
Vildagliptin Tablets 50mg
Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.
Vildagliptin 50mg + Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 50mg + Metformin Hydrochloride 1000mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 50mg + Metformin Hydrochloride 850mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Remogliflozin Etabonate 100mg + Vildagliptin 50mg Tablets
Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.
Vildaglipitin 100mg Extended Release Tablets
Vildaglipitin 100mg Extended Release Tablets is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.
Dapagliflozin 10mg + Vildagliptin (Sustained release)100mg Tablets
Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.
Dapagliflozin 5mg + Vildagliptin (Sustained release)100mg Tablets
Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.
Remogliflozin Etabonate 100mg + Vildagliptin 50mg + Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 100mg + Metformin Hydrochloride (sustained release) 1000mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 100mg + Metformin Hydrochloride (sustained release) 500mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 50mg + Metformin Hydrochloride (sustained release) 1000mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 50mg + Metformin Hydrochloride (sustained release) 500mg Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Dapagliflozin 10mg + Vildagliptin 100mg (SR) + Metformin Hydrochloride 1000mg (SR) Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Dapagliflozin 10mg + Vildagliptin 100mg (SR) + Metformin Hydrochloride 500mg (SR) Tablets
Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
Vildagliptin 50mg + Dapagliflozin 5mg Tablets
Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Vildagliptin.
Frequently Asked Questions (FAQ)
Get answers to common queries about Vildagliptin generics.